Myomo (MYO) Cash, Cash Equivalents, Marketable Securities : $10.96 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Myomo Cash, Cash Equivalents, Marketable Securities?

Myomo's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($11.12 Mil) to Dec. 2023 ($8.87 Mil) but then increased from Dec. 2023 ($8.87 Mil) to Mar. 2024 ($10.96 Mil).

Myomo's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($15.52 Mil) to Dec. 2022 ($5.35 Mil) but then increased from Dec. 2022 ($5.35 Mil) to Dec. 2023 ($8.87 Mil).

Myomo Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Myomo's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myomo Cash, Cash Equivalents, Marketable Securities Chart

Myomo Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

4.47

12.24

15.52

5.35

8.87

Myomo Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															9.26	8.96	11.12	8.87	10.96

Myomo Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Myomo (AMEX:MYO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Myomo Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Myomo's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Myomo (MYO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Myomo Inc (AMEX:MYO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

0M61:Germany 0M61:Germany

Address

137 Portland Street, 4th Floor, Boston, MA, USA, 02114

Website

https://www.myomo.com

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The Company provides the device to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The Company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).

Executives

Thomas F Kirk	director
Milton Mayo Morris	director	2121 ALLEN PARKWAY, APT 4075, HOUSTON TX 77019
Paul R Gudonis	director, officer: Chief Executive Officer	9 HICKORY ROAD, MANCHESTER MA 01944
David A Henry	officer: Chief Financial Officer
Harry Kovelman	officer: Chief Medical Officer	C/O MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Yitzchak Jacobovitz	director	MYOMO, INC., 137 PORTLAND ST., 4TH FLOOR, BOSTON MA 02114
Micah Mitchell	officer: Chief Commercial Officer	C/O MYOMO, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA 02139
Crowley Thomas Aloysius Jr.	director	19 ST CLAIR AV, SPRING LAKE NJ 07762
Cliff Conneighton	officer: Chief Marketing Officer	53 DEPOT ROAD, HOLLS NH 03049
Jonathan Naft	officer: VP, General Manager	C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Brandon M Green	officer: Chief Medical Officer	C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Ralph A Goldwasser	officer: Chief Financial Officer	BNN CORP, 150 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Davie Mendelsohn	officer: VP, Sales	C/O MYOMO, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Steve Sanghi	director	2355 W CHANDLER BLVD, CHANDLER AZ 85224-6199
Amy K. Knapp	director	75 N. MOUNTAIN AVE, MONTCLAIR NJ 07042